$ATRA mention timeline

Atara Biotherapeutics. Every tracked FinTwit mention of $ATRA, newest first. 21 mentions since the first on Jul 15, 2025. See the price chart.

May 2026 · 8 mentions

May 8
Jacob Plieth — The $ATRA Ebvallo soap opera - expect more soon. Via @ApexOnco -> https://t.co/CwRWC7gp8O↗
May 7
Jacob Plieth — Read $ATRA PR carefully: FDA agreed that a (not the) single-arm study could (not would) serve. P Fabre intends to submit updated Allele dataset. Nowhere does it say the FDA has a…↗
May 7
Jacob Plieth — There isn't a cat in hell's chance that $ATRA gets away with just resubmitting the Allele data.↗
May 7
Jacob Plieth — Well worth rereading the Jan 2026 $ATRA Ebvallo CRL, which lists a host of problems with the Allele study, not just the fact it was uncontrolled: unplanned efficacy analysis, high…↗
May 7
Jacob Plieth — So, to recap $ATRA: Jan 2026: "In the new CRL FDA stated that it no longer considers the single-arm study to be adequate." May 2026: "FDA agreed that a single-arm study could serve…↗
May 7
Jacob Plieth — $ATRA to be continued...? https://t.co/FMBqnZ3z2v↗
May 7
Jacob Plieth — Remember this verbatim from $ATRA, in case the FDA meeting notes ever come to light: "FDA agreed that a single arm study using an appropriate historical control ... could serve as…↗
May 7
Adam Feuerstein ✡️ — An important update to the $ATRA / Pierre Fabre Ebvallo story just breaking: FDA to reconsider treatment for rare cancer after its surprise rejection https://t.co/8zQSb7q5jU↗

Mar 19
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter: Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era $REPL Pierre Fabre $ATRA $QURE $CAPR $RGNX https://t.co…↗
Mar 12
Adam Feuerstein ✡️ — Pierre Fabre and $ATRA said FDA meeting to discuss the Ebvallo CRL has been scheduled. (Likely occuring within the next month.)↗

Feb 25
Adam Feuerstein ✡️ — New reporting from me on the FDA's rejection of Ebvallo, the cell therapy from $ATRA and Pierre Fabre intended for patients w/ a rare (and rapidly fatal) blood cancer. In late 202…↗
Feb 12
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter: The old Vinay Prasad never left. He just changed jobs Submissions to the FDA are handled by teams of reviewers, of course. But when I lo…↗

Jan 12
Jacob Plieth — @adamfeuerstein Bear in mind also that at the point when Makary was doing this (Sunday) he already knew $ATRA had been issued a CRL. Wild! #JPM26↗
Jan 12
Jacob Plieth — I guess this adds insult to injury $ATRA https://t.co/17CTRN1i2J↗
Jan 12
Jacob Plieth — Statement from Pierre Fabre re $ATRA CRL https://t.co/V9fHHACgGC↗
Jan 12
Adam Feuerstein ✡️ — Sunday: FDA tells cell and gene therapy developers not to worry about manufacturing. We got you, it's all good. We're here to help you. Marty Makary is walking through SFO shooting…

Sep 4
Jacob Plieth — Quite a few (redacted) oncology CRLs released then: $REGN odronextamab x3 SC Rybrevant $JNJ $REPL $ATRA Patri-dxd $MRK $DSNKY Camrelizumab + rivoceranib x2↗

Jul 29
Jacob Plieth — Stark lessons for cell therapy players from recent $ADAP $IOVA $ATRA disasters about the need for buy-in from a wealthy partner with commercial infrastructure.↗
Jul 15
Jacob Plieth — How $ATRA turned $60m into $40m↗